State Street Corp Kinnate Biopharma Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.33 - $6.84 $942,303 - $2.77 Million	-404,422 Reduced 86.71%	61,959 $187,000
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $11,068 - $25,528	3,199 Added 0.69%	466,381 $2.91 Million
Q4 2022 Feb 14, 2023	SELL	$5.26 - $12.19 $17,563 - $40,702	-3,339 Reduced 0.72%	463,182 $2.83 Million
Q3 2022 Nov 15, 2022	BUY	$9.86 - $15.76 $140,435 - $224,469	14,243 Added 3.15%	466,521 $5.58 Million
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $216,391 - $378,612	29,124 Added 6.88%	452,278 $5.7 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $264,551 - $615,689	34,224 Added 8.8%	423,154 $4.77 Million
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $929,857 - $1.44 Million	56,355 Added 16.95%	388,930 $6.89 Million
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $1.7 Million - $2.37 Million	95,445 Added 40.25%	332,575 $7.66 Million
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $1.19 Million - $1.7 Million	53,848 Added 29.38%	237,130 $5.52 Million
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $4.95 Million - $7.33 Million	183,282 New	183,282 $5.71 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.